This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Thorsten Stafforst remembers being told to stop ...
On October 16, a biotechnology company in Massachusetts in the U.S. named Wave Life Sciences made headlines for becoming the first company to treat a genetic condition by editing RNA at the clinical ...
The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...
Achieved proof-of-mechanism for Wave's RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous "MZ” genotype with low risk of AATD lung and liver ...
AIRNA is expected to file clinical trial application for optimized product candidate (AIR-001) with potential best-in-class profile for AATD in 2H 2025 CAMBRIDGE, Mass. &, TÜBINGEN, Germany, May 13, ...
Like the find-and-replace feature of a word processor, CRISPR-based engineering allows scientists to quickly and efficiently edit DNA sequences with base pair precision. Lauded as the great ...
Genetic editing holds promise to treat incurable diseases, but the most popular method — CRISPR — sometimes does more harm than good. A new study from University of California San Diego and Yale ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results